BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17875876)

  • 1. Familial acanthosis nigricans due to K650T FGFR3 mutation.
    Berk DR; Spector EB; Bayliss SJ
    Arch Dermatol; 2007 Sep; 143(9):1153-6. PubMed ID: 17875876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mild achondroplasia/hypochondroplasia with acanthosis nigricans, normal development, and a p.Ser348Cys FGFR3 mutation.
    Couser NL; Pande CK; Turcott CM; Spector EB; Aylsworth AS; Powell CM
    Am J Med Genet A; 2017 Apr; 173(4):1097-1101. PubMed ID: 28181399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial acanthosis nigricans with p.K650T FGFR3 mutation.
    Fukuchi K; Tatsuno K; Matsushita K; Kubo A; Ito T; Tokura Y
    J Dermatol; 2018 Feb; 45(2):207-210. PubMed ID: 29068064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Case of a Japanese female presenting severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) syndrome with a K650M mutation in the fibroblast growth factor receptor 3 gene].
    Adachi M
    No To Hattatsu; 2008 Nov; 40(6):478-82. PubMed ID: 19039991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acanthosis nigricans and hypochondroplasia in a child with a K650Q mutation in FGFR3.
    Berk DR; Boente Mdel C; Montanari D; Toloza MG; Primc NB; Prado MI; Bayliss SJ; Pique LM; Schrijver I
    Pediatr Dermatol; 2010; 27(6):664-6. PubMed ID: 21510009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3.
    Bellus GA; Bamshad MJ; Przylepa KA; Dorst J; Lee RR; Hurko O; Jabs EW; Curry CJ; Wilcox WR; Lachman RS; Rimoin DL; Francomano CA
    Am J Med Genet; 1999 Jul; 85(1):53-65. PubMed ID: 10377013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acanthosis nigricans in a Chinese girl with FGFR3 K650 T mutation: a case report and literature review.
    Fu J; Zhao Y; Wang T; Zhang Q; Xiao X
    BMC Med Genet; 2019 Jan; 20(1):8. PubMed ID: 30635042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial acanthosis nigricans with the FGFR3 mutation: Differences of pigmentation between male and female patients.
    Yasuda M; Morimoto N; Shimizu A; Toyoshima T; Yokoyama Y; Ishikawa O
    J Dermatol; 2018 Nov; 45(11):1357-1361. PubMed ID: 30168875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene.
    Tavormina PL; Bellus GA; Webster MK; Bamshad MJ; Fraley AE; McIntosh I; Szabo J; Jiang W; Jabs EW; Wilcox WR; Wasmuth JJ; Donoghue DJ; Thompson LM; Francomano CA
    Am J Hum Genet; 1999 Mar; 64(3):722-31. PubMed ID: 10053006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acanthosis nigricans in children and Crouzon syndrome].
    Lagaude M; Barreau M; Jokic M; Gerard M; DiRocco F; Hadj-Rabia S; Dompmartin A; Verneuil L
    Ann Dermatol Venereol; 2014 Nov; 141(11):685-8. PubMed ID: 25442473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.
    Meyers GA; Orlow SJ; Munro IR; Przylepa KA; Jabs EW
    Nat Genet; 1995 Dec; 11(4):462-4. PubMed ID: 7493034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autosomal dominant familial acanthosis nigricans caused by a C-terminal nonsense mutation of FGFR3.
    Tahara U; Yasuda M; Yamada Y; Aoki S; Sato S; Amagai M; Kubo A
    J Hum Genet; 2021 Aug; 66(8):831-834. PubMed ID: 33580140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prenatal and postnatal presentation of severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) due to the FGFR3 Lys650Met mutation.
    Zankl A; Elakis G; Susman RD; Inglis G; Gardener G; Buckley MF; Roscioli T
    Am J Med Genet A; 2008 Jan; 146A(2):212-8. PubMed ID: 18076102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3 mutations and the skin: report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature.
    Blomberg M; Jeppesen EM; Skovby F; Benfeldt E
    Dermatology; 2010; 220(4):297-305. PubMed ID: 20453470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crouzon syndrome with acanthosis nigricans: a case-based update.
    Di Rocco F; Collet C; Legeai-Mallet L; Arnaud E; Le Merrer M; Hadj-Rabia S; Renier D
    Childs Nerv Syst; 2011 Mar; 27(3):349-54. PubMed ID: 21136065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous features of Crouzon syndrome with acanthosis nigricans.
    Mir A; Wu T; Orlow SJ
    JAMA Dermatol; 2013 Jun; 149(6):737-41. PubMed ID: 23571469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment by glycolic acid peeling for cutaneous manifestation of familial generalized acanthosis nigricans caused by FGFR3 mutation.
    Ichiyama S; Funasaka Y; Otsuka Y; Takayama R; Kawana S; Saeki H; Kubo A
    J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):442-5. PubMed ID: 26818779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans.
    Vajo Z; Francomano CA; Wilkin DJ
    Endocr Rev; 2000 Feb; 21(1):23-39. PubMed ID: 10696568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acanthosis nigricans and insulin sensitivity in patients with achondroplasia and hypochodroplasia due to FGFR3 mutations.
    Alatzoglou KS; Hindmarsh PC; Brain C; Torpiano J; Dattani MT
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3959-63. PubMed ID: 19622626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical sirolimus therapy for epidermal nevus with features of acanthosis nigricans.
    Dodds M; Maguiness S
    Pediatr Dermatol; 2019 Jul; 36(4):554-555. PubMed ID: 30983034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.